United States Immunoassay Market Set for Steady Expansion Driven by Rising Chronic Disease Burden and Technological Advancements in Diagnostics

The United States immunoassay market, valued at US$35.5 billion in 2025, is projected to reach US$47.7 billion by 2030, advancing at a CAGR of 6.1% during the forecast period. Growth is driven by increasing diagnostic demand for infectious and chronic diseases, rising investments in R&D, and continuous technological advancements in immunodiagnostic platforms. With healthcare systems emphasizing early detection, personalized medicine, and preventive care, immunoassay technologies have become indispensable tools across hospitals, clinical laboratories, and biotechnology companies.

Immunoassays — analytical techniques that detect or quantify specific molecules through antigen-antibody interactions — play a pivotal role in disease diagnosis, therapeutic monitoring, and drug discovery. In recent years, the market has evolved with the integration of automated analyzers, high-throughput platforms, and multiplex assays capable of simultaneously detecting multiple biomarkers with high accuracy and efficiency.

Download PDF Brochure of Immunoassay Market

Market Overview: Diagnostic Innovation Transforming Healthcare

The immunoassay industry has undergone a transformative shift with the growing adoption of chemiluminescent immunoassay (CLIA), enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (RIA) technologies. These advanced platforms enable rapid, reliable, and cost-effective testing for a wide range of conditions, including infectious diseases, cardiovascular disorders, cancer, autoimmune diseases, and endocrinological disorders.

A significant driver of this transformation is the increasing prevalence of lifestyle-related diseases and the global focus on healthcare preparedness, especially following the COVID-19 pandemic. Immunoassays are now integral to routine diagnostics, pandemic surveillance, and vaccine efficacy monitoring. Additionally, automation and digitalization in laboratories are streamlining testing workflows, enhancing productivity, and minimizing human error — critical for maintaining consistent accuracy across large testing volumes.

The emergence of point-of-care (POC) immunoassays and home-based testing kits is further expanding accessibility, enabling rapid results in decentralized settings. This trend aligns with the healthcare sector’s push toward patient-centered, real-time diagnostics, especially for chronic disease management and early intervention.

Key Market Drivers

1. Rising Prevalence of Chronic and Infectious Diseases

The growing incidence of conditions such as diabetes, cancer, cardiovascular disorders, and infectious diseases like HIV and hepatitis continues to drive demand for immunoassay-based diagnostic tests. Early disease detection through immunoassays allows for timely treatment, reducing overall healthcare costs and improving patient outcomes.

2. Technological Advancements and Automation

Continuous innovation in assay design, detection systems, and automation has significantly enhanced testing precision and throughput. Modern automated analyzers integrated with AI and cloud-based data management systems enable high-speed processing and advanced diagnostic interpretation, reducing manual intervention.

3. Expansion of Personalized Medicine and Biomarker Discovery

The growth of precision medicine has fueled biomarker research, leading to the development of tailored immunoassay panels that support individualized treatment decisions. Pharmaceutical and biotech companies increasingly rely on immunoassays during drug discovery, clinical trials, and therapeutic monitoring.

4. Growing Use of Immunoassays in Emerging Applications

Beyond traditional diagnostics, immunoassays are gaining traction in therapeutic drug monitoring, allergy testing, and environmental analysis. This broadening application scope is reinforcing their importance across both clinical and industrial sectors.

5. Increased Investment in Healthcare Infrastructure

Rising healthcare expenditure, modernization of laboratory facilities, and favorable government initiatives aimed at improving diagnostic capabilities are strengthening the country’s diagnostic testing ecosystem, creating sustained opportunities for immunoassay adoption.

Market Segmentation Insights

• By Product Type:

The market is categorized into reagents & kits, analyzers, and software & services. Among these, reagents & kits dominate due to their recurrent usage and critical role in test performance. The analyzers segment is growing rapidly as hospitals and laboratories embrace automated systems to improve operational efficiency.

• By Technology:

Key technologies include ELISA, RIA, CLIA, fluorescence immunoassay (FIA), and rapid test immunoassays. The CLIA segment holds the largest share, owing to its superior sensitivity and capability for multiplex testing. Rapid test immunoassays, including lateral flow assays, are gaining momentum for POC diagnostics and self-testing.

• By Application:

Immunoassays are extensively used in infectious disease testing, oncology, endocrinology, cardiology, autoimmune disorders, and drug monitoring. The infectious disease segment remains the largest, while the oncology segment is witnessing accelerated growth with the rising demand for tumor marker testing.

• By End User:

Major end users include hospitals, diagnostic laboratories, research institutes, and pharmaceutical & biotechnology companies. Hospitals and diagnostic labs dominate the market, supported by high test volumes and infrastructure investments. Biotech firms represent a growing segment, utilizing immunoassays for R&D and drug development.

Industry Dynamics and Trends

The United States remains a global leader in immunodiagnostics, supported by a robust healthcare infrastructure, strong R&D ecosystem, and the presence of leading global manufacturers. Advancements in microfluidics, nanotechnology, and biosensor integration are accelerating innovation in next-generation immunoassays, enabling faster turnaround times and enhanced analytical accuracy.

Moreover, the increasing use of AI-driven analytics and machine learning algorithms is helping laboratories interpret complex immunoassay data, predict disease progression, and improve diagnostic precision. The adoption of lab automation and robotics is reducing operational costs while maintaining stringent quality standards — a crucial factor for large-scale testing facilities.

The rise in home-based and wearable diagnostic solutions also reflects a shift toward decentralized healthcare delivery. Companies developing compact immunoassay platforms are focusing on smartphone-connected and digital reader technologies to expand patient access to high-quality diagnostics beyond clinical environments.

Competitive Landscape

The competitive landscape features a mix of multinational corporations and innovative biotech firms specializing in assay development, analyzer design, and diagnostic automation. Prominent players include:

• Abbott Laboratories – A global leader in immunoassay technology with extensive CLIA and rapid test platforms.

• Roche Diagnostics – Offers advanced automated immunoassay analyzers integrated with AI-driven diagnostic software.

• Siemens Healthineers – Focused on high-throughput immunoassay systems for hospitals and centralized labs.

• Danaher Corporation (Beckman Coulter) – Pioneering integrated solutions for precision diagnostics and laboratory automation.

• bioMérieux SA – Specializes in infectious disease diagnostics through high-performance immunoassay systems.

• Thermo Fisher Scientific – Expanding into multiplex immunoassay technologies for research and clinical applications.

Strategic collaborations, acquisitions, and product innovations remain the primary growth strategies, with companies investing heavily in automation, miniaturization, and digital integration to meet evolving market demands.

Future Outlook and Emerging Opportunities

The next phase of growth in the immunoassay industry will be defined by technological convergence, digital transformation, and expansion into precision diagnostics. Future opportunities include:

• Integration of artificial intelligence to enhance test accuracy and accelerate result interpretation.

• Development of portable immunoassay analyzers for remote and home-based testing applications.

• Expansion of multiplex and ultra-sensitive immunoassays for early cancer and neurodegenerative disease detection.

• Increased focus on sustainability through eco-friendly reagent formulations and reusable test components.

• Collaborative R&D partnerships between academic institutions, startups, and established diagnostics companies to accelerate innovation.

By 2030, immunoassay systems are expected to become fully digitalized, connected, and integrated into electronic health record (EHR) ecosystems, providing seamless, real-time diagnostic insights for clinicians and patients alike.

Conclusion

The United States immunoassay market is poised for sustained and technology-driven expansion, supported by growing healthcare needs, diagnostic innovation, and investment in R&D infrastructure. As healthcare systems transition toward preventive and precision medicine, immunoassay technologies will remain at the forefront of diagnostic evolution.

Driven by automation, artificial intelligence, and increasing test accessibility, the immunoassay industry will continue to play a crucial role in advancing early disease detection, enhancing treatment precision, and improving healthcare outcomes across the nation.